229 related articles for article (PubMed ID: 25407271)
1. MEK1/2 inhibitor U0126 but not endothelin receptor antagonist clazosentan reduces upregulation of cerebrovascular contractile receptors and delayed cerebral ischemia, and improves outcome after subarachnoid hemorrhage in rats.
Povlsen GK; Edvinsson L
J Cereb Blood Flow Metab; 2015 Feb; 35(2):329-37. PubMed ID: 25407271
[TBL] [Abstract][Full Text] [Related]
2. Improvement in neurological outcome and abolition of cerebrovascular endothelin B and 5-hydroxytryptamine 1B receptor upregulation through mitogen-activated protein kinase kinase 1/2 inhibition after subarachnoid hemorrhage in rats.
Larsen CC; Povlsen GK; Rasmussen MN; Edvinsson L
J Neurosurg; 2011 Apr; 114(4):1143-53. PubMed ID: 20597604
[TBL] [Abstract][Full Text] [Related]
3. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats.
Schubert GA; Schilling L; Thomé C
J Neurosurg; 2008 Dec; 109(6):1134-40. PubMed ID: 19035733
[TBL] [Abstract][Full Text] [Related]
4. Effect of delayed cerebral vasospasm on cerebrovascular endothelin A receptor expression and function.
Vatter H; Konczalla J; Weidauer S; Preibisch C; Zimmermann M; Raabe A; Seifert V
J Neurosurg; 2007 Jul; 107(1):121-7. PubMed ID: 17639881
[TBL] [Abstract][Full Text] [Related]
5. MEK1/2 inhibitor U0126, but not nimodipine, reduces upregulation of cerebrovascular contractile receptors after subarachnoid haemorrhage in rats.
Christensen ST; Johansson SE; Radziwon-Balicka A; Warfvinge K; Haanes KA; Edvinsson L
PLoS One; 2019; 14(4):e0215398. PubMed ID: 30978262
[TBL] [Abstract][Full Text] [Related]
6. Early MEK1/2 inhibition after global cerebral ischemia in rats reduces brain damage and improves outcome by preventing delayed vasoconstrictor receptor upregulation.
Johansson SE; Larsen SS; Povlsen GK; Edvinsson L
PLoS One; 2014; 9(3):e92417. PubMed ID: 24642693
[TBL] [Abstract][Full Text] [Related]
7. Microvasospasms After Experimental Subarachnoid Hemorrhage Do Not Depend on Endothelin A Receptors.
Liu H; Dienel A; Schöller K; Schwarzmaier SM; Nehrkorn K; Plesnila N; Terpolilli NA
Stroke; 2018 Mar; 49(3):693-699. PubMed ID: 29438081
[TBL] [Abstract][Full Text] [Related]
8. Early events triggering delayed vasoconstrictor receptor upregulation and cerebral ischemia after subarachnoid hemorrhage.
Povlsen GK; Johansson SE; Larsen CC; Samraj AK; Edvinsson L
BMC Neurosci; 2013 Mar; 14():34. PubMed ID: 23496889
[TBL] [Abstract][Full Text] [Related]
9. ERK1/2 inhibition attenuates cerebral blood flow reduction and abolishes ET(B) and 5-HT(1B) receptor upregulation after subarachnoid hemorrhage in rat.
Beg SA; Hansen-Schwartz JA; Vikman PJ; Xu CB; Edvinsson LI
J Cereb Blood Flow Metab; 2006 Jun; 26(6):846-56. PubMed ID: 16251886
[TBL] [Abstract][Full Text] [Related]
10. Rapid functional upregulation of vasocontractile endothelin ETB receptors in rat coronary arteries.
Skovsted GF; Pedersen AF; Larsen R; Sheykhzade M; Edvinsson L
Life Sci; 2012 Oct; 91(13-14):593-9. PubMed ID: 22391414
[TBL] [Abstract][Full Text] [Related]
11. Proteomic Expression Changes in Large Cerebral Arteries After Experimental Subarachnoid Hemorrhage in Rat Are Regulated by the MEK-ERK1/2 Pathway.
Müller AH; Edwards AVG; Larsen MR; Nielsen J; Warfvinge K; Povlsen GK; Edvinsson L
J Mol Neurosci; 2017 Aug; 62(3-4):380-394. PubMed ID: 28741142
[TBL] [Abstract][Full Text] [Related]
12. CaMKII inhibition with KN93 attenuates endothelin and serotonin receptor-mediated vasoconstriction and prevents subarachnoid hemorrhage-induced deficits in sensorimotor function.
Edvinsson L; Povlsen GK; Ahnstedt H; Waldsee R
J Neuroinflammation; 2014 Dec; 11():207. PubMed ID: 25498987
[TBL] [Abstract][Full Text] [Related]
13. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.
Chen G; Tariq A; Ai J; Sabri M; Jeon HJ; Tang EJ; Lakovic K; Wan H; Macdonald RL
Brain Res; 2011 May; 1392():132-9. PubMed ID: 21466789
[TBL] [Abstract][Full Text] [Related]
14. From bench-to-bedside in catastrophic cerebrovascular disease: development of drugs targeting the endothelin axis in subarachnoid hemorrhage-related vasospasm.
Ardelt A
Neurol Res; 2012 Mar; 34(2):195-210. PubMed ID: 22333896
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase C inhibition prevents upregulation of vascular ET(B) and 5-HT(1B) receptors and reverses cerebral blood flow reduction after subarachnoid haemorrhage in rats.
Beg SS; Hansen-Schwartz JA; Vikman PJ; Xu CB; Edvinsson LI
J Cereb Blood Flow Metab; 2007 Jan; 27(1):21-32. PubMed ID: 16736053
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin-1 receptor antagonism in a rat model of subarachnoid hemorrhage: prevention of upregulation of contractile ETB and 5-HT1B receptors and cerebral blood flow reduction.
Ansar S; Svendgaard NA; Edvinsson L
J Neurosurg; 2007 May; 106(5):881-6. PubMed ID: 17542534
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan.
Sabri M; Ai J; Macdonald RL
Stroke; 2011 May; 42(5):1454-60. PubMed ID: 21454820
[TBL] [Abstract][Full Text] [Related]
18. Regulation of enhanced cerebrovascular expression of proinflammatory mediators in experimental subarachnoid hemorrhage via the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway.
Maddahi A; Povlsen GK; Edvinsson L
J Neuroinflammation; 2012 Dec; 9():274. PubMed ID: 23259581
[TBL] [Abstract][Full Text] [Related]
19. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm.
Roux S; Breu V; Giller T; Neidhart W; Ramuz H; Coassolo P; Clozel JP; Clozel M
J Pharmacol Exp Ther; 1997 Dec; 283(3):1110-8. PubMed ID: 9399983
[TBL] [Abstract][Full Text] [Related]
20. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
Shen J; Pan JW; Fan ZX; Xiong XX; Zhan RY
J Neurosurg; 2013 Jul; 119(1):180-9. PubMed ID: 23641823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
